Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2015-06-25

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1586/17512433.2015.1050379PMID 26109097
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AB0179 Revision of European Medicine Agency's (EMA) Guideline on Clinical Investigation of Medicinal Products Other than Nsaids for Treatment of Rheumatoid Arthritis, 2016

  2016cited by this paper
• Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA

  2015cited by this paper
• Long-term outcomes of pharmacologically treated versus non-treated adults with ADHD and substance use disorder: a naturalistic study.

  2015cited by this paper
• Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.

  2015cited by this paper
• The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research

  2015cited by this paper
• Improved but Still Impaired: Symptom-Impairment Correspondence Among Youth With Attention-Deficit Hyperactivity Disorder Receiving Community-Based Care

  2015cited by this paper
• The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research

  2015cited by this paper
• Cognitive Training for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials

  2015cited by this paper
• Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway

  2015cited by this paper
• Methylphenidate and the Risk of Trauma

  2015cited by this paper
• Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study.

  2015cited by this paper
• Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.

  2014cited by this paper
• Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

  2014cited by this paper
• Cardiovascular Safety of Stimulants in Children with Attention-Deficit/Hyperactivity Disorder: A Nationwide Prospective Cohort Study

  2014cited by this paper
• Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy.

  2014cited by this paper
• 15. CADDRA. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). 3rd ed. Toronto, ON: Canadian ADHD Practice Guidelines; 2011.

  2014cited by this paper
• Consequences of ADHD medication use for children's outcomes.

  2014cited by this paper
• Participant-Perceived Quality of Life in a Long-Term, Open-Label Trial of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder

  2014cited by this paper
• Editorial: Acknowledging complexity and heterogeneity in causality--implications of recent insights into neuropsychology of childhood disorders for clinical practice.

  2014cited by this paper
• The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6 to 12 Years of Age With ADHD in a Double-Blind Placebo-Controlled Trial

  2014cited by this paper
• Self-Reported Quality of Life of Young Children With Conditions From Early Infancy: A Systematic Review

  2014cited by this paper
• Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis.

  2014cited by this paper
• The use of actigraphy in the monitoring of methylphenidate versus placebo in ADHD: a meta-analysis

  2014cited by this paper
• Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions

  2014cited by this paper
• Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.

  2014cited by this paper
• Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis.

  2014cited by this paper
• Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder

  2014cited by this paper
• Treatment Response and Remission in a Double-Blind, Randomized, Head-to-Head Study of Lisdexamfetamine Dimesylate and Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder

  2014cited by this paper
• European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.

  2013cited by this paper
• A longitudinal examination of neuropsychological and clinical functioning in boys with attention deficit hyperactivity disorder (ADHD): improvements in executive functioning do not explain clinical improvement

  2013cited by this paper
• Obesity in Men With Childhood ADHD: A 33-Year Controlled, Prospective, Follow-up Study

  2013cited by this paper
• Does neurocognitive functioning predict future or persistence of ADHD? A systematic review.

  2013cited by this paper
• Does childhood attention-deficit/hyperactivity disorder predict risk-taking and medical illnesses in adulthood?

  2013cited by this paper
• Long-Term Quality-of-Life and Functioning Comparison of Atomoxetine Versus Other Standard Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder

  2013cited by this paper
• A Post Hoc Comparison of the Effects of Lisdexamfetamine Dimesylate and Osmotic-Release Oral System Methylphenidate on Symptoms of Attention-Deficit Hyperactivity Disorder in Children and Adolescents

  2013cited by this paper
• Comparison of child self-reports and parent proxy-reports on quality of life of children with attention deficit hyperactivity disorder

  2013cited by this paper
• A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making and variability in attention deficit hyperactivity disorder: advancing beyond the three-pathway models

  2013cited by this paper
• Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries

  2013cited by this paper
• Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder

  2013cited by this paper
• Parent-Reported Executive Function Behaviors and Clinician Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms in Children Treated with Lisdexamfetamine Dimesylate

  2013cited by this paper
• Effect of Methylphenidate and Folic Acid on ADHD Symptoms and Quality of Life and Aggression: A Randomized Double Blind Placebo Controlled Clinical Trial

  2013cited by this paper
• Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison

  2013cited by this paper
• Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder

  2013cited by this paper
• Do stimulants improve functioning in adults with ADHD? A review of the literature.

  2013cited by this paper
• Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.

  2013cited by this paper
• Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.

  2013cited by this paper
• ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults

  2013cited by this paper
• Health-Related Quality of Life in Gilles de la Tourette Syndrome: A Decade of Research

  2013cited by this paper
• Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

  2012cited by this paper
• The Affective Reactivity Index: a concise irritability scale for clinical and research settings

  2012cited by this paper
• Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later.

  2012cited by this paper
• Medication for attention deficit-hyperactivity disorder and criminality.

  2012cited by this paper
• Guanfacine Extended Release as Adjunctive Therapy to Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

  2012cited by this paper
• Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review.

  2012cited by this paper
• Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design

  2012cited by this paper
• Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

  2012cited by this paper
• Comparing Four Methods of Integrating Parent and Teacher Symptom Ratings of Attention-deficit/hyperactivity Disorder (ADHD)

  2012cited by this paper
• Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings

  2011cited by this paper
• Efficacy of a Methylphenidate Transdermal System Versus t.i.d. Methylphenidate in a Laboratory Setting

  2011cited by this paper
• Clonidine Extended-Release Tablets as Add-on Therapy to Psychostimulants in Children and Adolescents With ADHD

  2011cited by this paper
• Efficacy of Methylphenidate for Adults with Attention-Deficit Hyperactivity Disorder

  2011cited by this paper
• Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.

  2011cited by this paper
• Dose Effects and Comparative Effectiveness of Extended Release Dexmethylphenidate and Mixed Amphetamine Salts

  2011cited by this paper
• Health-related quality of life in children and adolescents with autism spectrum disorder.

  2011cited by this paper
• Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder

  2011cited by this paper
• ADHD drugs and serious cardiovascular events in children and young adults.

  2011cited by this paper
• Pragmatic measures in paediatric psychopharmacology--are we getting it right?

  2011cited by this paper
• Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

  2011cited by this paper
• The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults.

  2010cited by this paper
• European guidelines on managing adverse effects of medication for ADHD

  2010cited by this paper
• Improvements in Executive Function Correlate with Enhanced Performance and Functioning and Health-Related Quality of Life: Evidence from 2 Large, Double-Blind, Randomized, Placebo-Controlled Trials in ADHD

  2010cited by this paper
• Beyond the dual pathway model: evidence for the dissociation of timing, inhibitory, and delay-related impairments in attention-deficit/hyperactivity disorder.

  2010cited by this paper
• Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder

  2010cited by this paper
• Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD

  2010cited by this paper
• Attention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settings.

  2010cited by this paper
• What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD).

  2010cited by this paper
• The Impact of Medications on Quality of Life in Attention-Deficit Hyperactivity Disorder

  2010cited by this paper
• Diagnostic Instability of DSM–IV ADHD Subtypes: Effects of Informant Source, Instrumentation, and Methods for Combining Symptom Reports

  2010cited by this paper
• Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

  2010cited by this paper
• OSH Child and Adolescent Psychiatry

  2009cited by this paper
• The quality of life of children with attention deficit/hyperactivity disorder: a systematic review

  2009cited by this paper
• Are There Placebo Effects in the Medication Treatment of Children With Attention-Deficit Hyperactivity Disorder?

  2009cited by this paper
• Do Attention Deficits Influence IQ Assessment in Children and Adolescents With ADHD?

  2009cited by this paper
• Atomoxetine and Neuropsychological Function in Children With Attention-Deficit/Hyperactivity Disorder: Results of a Pilot Study

  2009cited by this paper
• Adverse Reactions to Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder: Structure and Associations with Clinical Characteristics and Symptom Control

  2009cited by this paper
• Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.

  2009influential reference
• Heterogeneity in ADHD: Neuropsychological Pathways, Comorbidity and Symptom Domains

  2009cited by this paper
• The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use.

  2008cited by this paper
• Effects of Methylphenidate on the Catecholaminergic System in Attention-Deficit/Hyperactivity Disorder

  2008cited by this paper
• Juvenile methylphenidate modulates reward‐related behaviors and cerebral blood flow by decreasing cortical D3 receptors

  2008cited by this paper
• Medications Do Not Necessarily Normalize Cognition in ADHD Patients

  2008cited by this paper
• Effect of stimulants on height and weight: a review of the literature.

  2008cited by this paper
• Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder

  2008cited by this paper
• A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.

  2007cited by this paper
• Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes.

  2007cited by this paper
• Is OPTAx™ useful for monitoring the effect of stimulants on hyperactivity and inattention?

  2007cited by this paper
• The worldwide prevalence of ADHD: a systematic review and metaregression analysis.

  2007cited by this paper
• The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder–Child Version: Psychometric Properties of an Adaptive Change Instrument

  2007cited by this paper
• The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder.

  2007cited by this paper
• Long-acting medications for the hyperkinetic disorders

  2006cited by this paper

• Can response to ADHD medication be predicted?

  2025cites this paper
• Treatment Adherence in ADHD: A Systematic Review of Influencing Factors and Strategies for Improvement.

  2025cites this paper
• Exploring the potential of Braingame Brian for executive function improvement in Spanish-speaking children with ADHD: A pilot study

  2024cites this paper
• An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder

  2023cites this paper
• Guidelines in the United States for the Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Why They Are Needed

  2023cites this paper
• Social gradient in use of health services and health‐related quality of life of children with attention‐deficit/hyperactivity disorder: A systematic review

  2023cites this paper
• The Impact of Childhood Attention-Deficit/Hyperactivity Disorder (ADHD) on Children’s Health-Related Quality of Life: A Systematic Review and Meta-Analysis

  2023cites this paper
• The Benefits and Limitations of Stimulants in Treating ADHD.

  2022cites this paper
• Self-management training vs. neurofeedback interventions for attention deficit hyperactivity disorder: Results of a randomized controlled treatment study

  2022cites this paper
• Can Neurocognitive Outcomes Assist Measurement-Based Care for Children with Attention-Deficit/Hyperactivity Disorder? A Systematic Review and Meta-Analyses of the Relationships Among the Changes in Neurocognitive Functions and Clinical Outcomes of Attention-Deficit/Hyperactivity Disorder in Pharmaco

  2022cites this paper
• Current Pharmacological Treatments for ADHD.

  2022cites this paper
• Effects of Combing Group Executive Functioning and Online Parent Training on School-Aged Children With ADHD: A Randomized Controlled Trial

  2022cites this paper
• Editorial: Comprehensive Child and Adolescent Mental Health Assessment Should Include Objective Assessments of Neurocognition.

  2021cites this paper
• The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG)

  2021cites this paper
• Examining the Educational Gap for Children with ADHD and Subthreshold ADHD

  2020cites this paper
• CDH13 and LPHN3 Gene Polymorphisms in Attention-Deficit/Hyperactivity Disorder: Their Relation to Clinical Characteristics

  2020cites this paper
• Post hoc analyses of response rates to pharmacological treatments in children and adolescents with attention-deficit/hyperactivity disorder

  2020cites this paper
• The relationship between maternal stress and boys' ADHD symptoms and quality of life: An Australian prospective cohort study.

  2020cites this paper
• Is 'minimally adequate treatment' really adequate? investigating the effect of mental health treatment on quality of life for children with mental health problems.

  2020cites this paper
• Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials.

  2019cites this paper
• ADHD Symptoms and Quality of Life Across a 12-Month Period in Children With ADHD: A Longitudinal Study

  2019cites this paper
• Genética y farmacogenética del trastorno por déficit de atención e hiperactividad en niños de la población española

  2017cites this paper
• Early diagnosis and treatment of ADHD are important for a secure transition to adolescence

  2017cites this paper
• Identification of biotypes in Attention-Deficit/Hyperactivity Disorder, a report from a randomized, controlled trial.

  2017cites this paper
• Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder

  2017cites this paper
• Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects

  2017cites this paper
• Assessment and monitoring of treatment response in adult ADHD patients: current perspectives

  2017cites this paper
• of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit / hyperactivity disorder

  2017cites this paper
• Organisation of services for managing ADHD

  2016cites this paper
• World Journal of Psychiatry

  year unknowncites this paper